COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Effect of Caffeine on the Narcoleptic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02832336
Recruitment Status : Completed
First Posted : July 14, 2016
Last Update Posted : March 1, 2019
King Saud Medical City
Information provided by (Responsible Party):
Mona Aldoasri, King Saud University

Brief Summary:
Caffeine may be playing a beneficial role in patients with narcolepsy. However, the relationship between caffeine and its effects on narcoleptic patients has not been examined, and it is also unclear whether caffeine provides a beneficial effect or not. Hence, the aim of this study is to assess the effects of caffeine consumption on daytime sleepiness and reaction time in narcoleptic patients.

Condition or disease Intervention/treatment Phase
Narcolepsy Drug: Vivarin Drug: Fiber Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial
Study Start Date : October 1, 2016
Actual Primary Completion Date : May 11, 2017
Actual Study Completion Date : May 7, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Caffeine

Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.

Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants.

Drug: Vivarin
Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
Other Names:
  • 1,3,7-Trimethylpurine-2,6-dione
  • C8H10N4O2
  • caffeine citrate

Placebo Comparator: Fiber
Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
Drug: Fiber
Fiber will be used as placebo.
Other Name: Nutrisource Fiber

Primary Outcome Measures :
  1. Eye Blink Measurement [ Time Frame: 7 days ]
    Blink total duration (BTD), which measures the duration of the closing, closed and reopening phases of each blink by using Optalert system, a glass frame carrying an IR transmitter and receiver bar that positioned below and in front of the eye, directed towards the lower edge of the upper eyelid allows for measurements of blink duration and eye closure time as an indicator of drowsiness and decreased vigilance.The eye blink measurement (Optalert) will be performed multiple times to measure the changes in the alertness level for each patient after single-dose intake and after daily medication intake.(The measuring instrument takes about 10-20 minutes).

Secondary Outcome Measures :
  1. Stanford Sleepiness Scale (SSS) [ Time Frame: 7 days ]
    SSS is a daytime sleepiness Scales, using a 7-point Likert scale based on a series of statements that range from "feeling active, vital, alert, wide awake" to "almost in reverie, cannot stay awake, sleep onset appears imminent" describes how they feel at the time (Hoddes,1973).

  2. The Karolinska Sleepiness Scale (KSS) [ Time Frame: 7 days ]
    KSS is a daytime sleepiness Scales, using a 9-point Likert scale based on a self-reported, subjective assessment of the subject's level of drowsiness at the time (Akerstedt & Gillberg, 1990).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Case -group should be Narcoleptic with cataplexy

Exclusion Criteria:

  • Individuals older than 45 years or younger than 18 years old.
  • Individuals complaining of any diseases or conditions that affect their dietary intake, as such : renal failure, liver failure, malabsorption problems, cardiac diseases … etc.
  • Individuals having hypersensitivity to caffeine.
  • Individuals with medical conditions that cause sleepiness (like hypothyroidism) and pregnant or lactating females will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02832336

Layout table for location information
Saudi Arabia
King Khalid University Hospital:King Saud Medical City
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Saud University
King Saud Medical City
Layout table for investigator information
Principal Investigator: Mona S Aldosari, Masteral King Saud University

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mona Aldoasri, Principal Investigator, King Saud University Identifier: NCT02832336    
Other Study ID Numbers: IRB:E-15-1484
SFDA # 16022302 ( Registry Identifier: Saudi Clinical Trials Registry )
First Posted: July 14, 2016    Key Record Dates
Last Update Posted: March 1, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Possibility to share most data.
Keywords provided by Mona Aldoasri, King Saud University:
Caffeine citrate
Neurological disorder
Excessive daytime sleepiness
adenosine antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Caffeine citrate
Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents